	Renal
CAIX
Monoclonal antibody
Therapy
VEGF
G250
RCC
	phase II trial
tumors
tumor cells
Bevacizumab treatment
RCC
Bevacizumab
renal cell carcinoma
clinical trials
patients
treatment
combination
disease
partial response
effects
renal masses
antigen
phase I trial
dose
trial
malignant cells
survival
molecular characterization
objective responses
RIT
action
VEGF levels
weeks
target molecules
VEGF
cG 250
study
I-G
result
diagnose
targets

